Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer

Volume: 12
Published: Jul 15, 2021
Abstract
Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until recently, there were limited therapeutic options. However, over the last decade our understanding of the molecular foundation of thyroid function and carcinogenesis has driven the development of many novel therapeutics. These include FDA approved tyrosine kinase inhibitors and small molecular inhibitors of VEGFR, BRAF, MEK, NTRK and RET, which...
Paper Details
Title
Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
Published Date
Jul 15, 2021
Volume
12
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.